MINNEAPOLIS, Feb. 24, 2015 /PRNewswire/ -- Uroplasty,
Inc. (NASDAQ: UPI), a medical device company that develops,
manufactures and markets innovative proprietary products to treat
voiding dysfunctions, today announced that Cigna has written a
positive coverage policy for Percutaneous Tibial Nerve Stimulation
(PTNS) delivered via Uroplasty's Urgent(R) PC Neuromodulation
System for treatment of overactive bladder (OAB) and associated
symptoms of urinary urgency, urinary frequency and urge
incontinence. The new policy applies to approximately 14 million
lives covered by Cigna and was effective February 15, 2015.
"This positive coverage decision by Cigna brings the total U.S.
access to Urgent PC therapy to approximately 123 million lives
covered by private payers in addition to over 50 million Medicare
beneficiaries," said Rob Kill,
President and CEO of Uroplasty. "This decision further illustrates
the medical necessity of PTNS and its value to patients and
physicians trying to manage the symptoms of OAB. Urgent PC is a
recommended third line treatment within the OAB treatment
guidelines for patients who have not responded or cannot tolerate
behavioral intervention and pharmacologic agents. The treatment
guidelines are issued jointly by the American Urology Association
(AUA) and Society for Urodynamics and Female Urology (SUFU).
About Overactive Bladder
Overactive bladder (OAB) is a
chronic condition that affects approximately 42 million US adults.
The symptoms include urinary urgency, frequency and urge
incontinence. The Urgent PC Neuromodulation System is the only
commercially available FDA cleared device that delivers
Percutaneous Tibial Nerve Stimulation (PTNS) therapy.
About Uroplasty
Uroplasty, Inc., headquartered in
Minnetonka, Minnesota, with
wholly-owned subsidiaries in The
Netherlands and the United
Kingdom, is a global medical device company that develops,
manufactures and markets innovative proprietary products for the
treatment of voiding dysfunctions. Uroplasty's focus is the
continued commercialization of its Urgent® PC Neuromodulation
System, which Uroplasty believes is the only commercially
available, FDA-cleared device that delivers percutaneous tibial
nerve stimulation (PTNS) for the office-based treatment of
overactive bladder (OAB). OAB is a chronic condition that
affects approximately 42 million U.S. adults. The symptoms
include urinary urgency, frequency and urge
incontinence. Uroplasty also offers Macroplastique®, an
injectable urethral bulking agent for the treatment of adult female
stress urinary incontinence primarily due to intrinsic sphincter
deficiency. For more information on Uroplasty and its
products, please visit Uroplasty, Inc. at www.uroplasty.com.
For Further
Information:
Uroplasty,
Inc.
Brett Reynolds, SVP
and CFO
952-426-6152
EVC Group
Doug Sherk/Brian
Moore (Investors)
415-652-9100/310-579-6199
Janine McCargo
(Media)
646-688-0425
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/uroplasty-announces-positive-coverage-decision-for-percutaneous-tibial-nerve-stimulation-by-cigna-300040102.html
SOURCE Uroplasty, Inc.